SEHK:2616
SEHK:2616Biotechs

Can CStone Pharmaceuticals' (SEHK:2616) Novel Antibody Drive a New Era in Allergy Treatment Innovation?

On November 7, 2025, CStone Pharmaceuticals presented promising preclinical data on its novel bispecific antibody, CS2015, at the ACAAI Annual Scientific Meeting in Orlando, showcasing its dual targeting of OX40L and TSLP in type 2 inflammation diseases. This marks the first time CS2015 has been presented at an international conference, highlighting potential advancements in therapies for allergies, asthma, and related conditions. We'll now explore how the innovative attributes of CS2015...
SEHK:6808
SEHK:6808Consumer Retailing

Assessing Sun Art Retail Group (SEHK:6808) Valuation After Weaker Earnings and Dividend Cut

Sun Art Retail Group (SEHK:6808) just released its half-year results, revealing a drop in sales and a shift from a profit last year to a net loss. In addition, the company reduced its interim dividend per share. See our latest analysis for Sun Art Retail Group. Following the weaker half-year results and trimmed dividend, Sun Art Retail Group’s 1-year share price return is down 8.6% year-to-date, with total shareholder return over the same period falling 4.5%. Momentum appears to be fading, as...
SEHK:1672
SEHK:1672Biotechs

Assessing Ascletis Pharma (SEHK:1672) Valuation After Promising Preclinical Results for Next-Gen Obesity Treatment

Ascletis Pharma (SEHK:1672) revealed new preclinical data for its once-monthly combination of ASC36 and ASC35, two next-generation peptides designed for obesity treatment. Early results suggest substantially greater body weight reduction compared to standard therapies. See our latest analysis for Ascletis Pharma. Momentum for Ascletis Pharma has picked up substantially, with its 1-month share price return rocketing 51.2% and a year-to-date gain of over 340% as positive data and pipeline...